Advertisement


Felix Y. Feng, MD, on Prostate Cancer: Choosing Patients Who May Benefit From Apalutamide

2021 Genitourinary Cancers Symposium

Advertisement

Felix Y. Feng, MD, of the University of California, San Francisco, discusses study findings showing that molecular determinants may help clinicians select patients with nonmetastatic castration-resistant prostate cancer who may derive the most benefit from apalutamide and other androgen-signaling inhibitors (Abstract 8).



Related Videos

Kidney Cancer

Sumanta K. Pal, MD, on Advanced RCC: Tivozanib to Treat Disease Progression After Axitinib

Sumanta K. Pal, MD, of City of Hope, discusses findings of the TIVO-3 study, which showed that the tyrosine kinase inhibitor tivozanib improved progression-free survival vs sorafenib in patients whose advanced renal cell carcinoma progressed after multiple lines of therapy (Abstract 278).

Kidney Cancer

Toni K. Choueiri, MD, on Clear Cell RCC: Treatment With Belzutifan Plus Cabozantinib

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discuses a preliminary phase II analysis of the HIF-2a inhibitor belzutifan in combination with cabozantinib, which showed antitumor activity in previously treated patients with metastatic clear cell renal cell carcinoma (Abstract 272).

Kidney Cancer
Immunotherapy

Elizabeth R. Plimack, MD, on RCC: Outcomes With Pembrolizumab Plus Axitinib

Elizabeth R. Plimack, MD, of Fox Chase Cancer Center, discusses phase III results from the KEYNOTE-426 study—specifically, an exploratory subgroup analysis of patients with advanced renal cell carcinoma who were randomly assigned to receive pembrolizumab plus axitinib and completed 2 years of treatment (Abstract 327).

Bladder Cancer
Kidney Cancer
Prostate Cancer

Christopher Sweeney, MBBS, and Thomas Powles, MD, PhD, on Treating GU Malignancies: Expert Views

A spirited discussion ensued when we asked Christopher Sweeney, MBBS, of Dana-Farber Cancer Institute, and Thomas Powles, MD, PhD, of Cancer Research UK Barts Centre, to compare notes on how they treat bladder, prostate, and kidney cancers.

Bladder Cancer

Daniel M. Geynisman, MD, on Bladder Cancer: Risk-Enabled Treatment After Neoadjuvant Chemotherapy

Daniel M. Geynisman, MD, of Fox Chase Cancer Center, discusses phase II results from the RETAIN BLADDER study, which sequenced bladder tumor samples while treating patients with neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. The goal was to increase metastasis-free survival and also preserve the bladder and quality of life (Abstract 397).

Advertisement

Advertisement



Advertisement